Palivizumab and emerging therapies for respiratory syncytial virus

Expert Opinion on Biological Therapy

Volumn 12, Issue 5, 2012, Pages 547-548

  Hoopes, John Michael ^a   Makari, Doris ^a   Groothuis, Jessie ^a  

^a MEDIMMUNE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MOTAVIZUMAB; PALIVIZUMAB;

ANTIVIRAL THERAPY; ASTHMA; CHRONIC LUNG DISEASE; CONGENITAL HEART DISEASE; CYSTIC FIBROSIS; DISEASE SEVERITY; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; GESTATIONAL AGE; HOSPITALIZATION; HUMAN; IMMUNOCOMPROMISED PATIENT; LETTER; PREMATURITY; RESPIRATORY SYNCYTIAL VIRUS INFECTION;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; HUMANS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL VACCINES;

RESPIRATORY SYNCYTIAL VIRUS;

EID: 84859583822     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.665048     Document Type: Letter

References (7)

1. Shadman KA, Wald ER. A review of palivizumab and emerging therapies for respiratory syncytial virus. Expert Opin Biol Ther 2011;11:1469-84
2. Astra-Zeneca. AstraZeneca discontinues development of motavizumab for RSV prophylaxis indication. Press release: 21 Dec 2010. Available from: http://www.astrazeneca.com/Media/Pressreleases?pageNumber=4 [Accessed on 7 November 2011]
3. IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998;102:531-7
4. MedImmune LLC. A Phase II randomized, double-blind, two-period cross-over study to evaluate the pharmacokinetics, safety and tolerability of a liquid formulation of palivizumab (MEDI-493, Synagis). NCT00240929. Available from: www.clinicaltrials.gov [Last updated 12 November 2010]
5. MedImmune LLC. A Study to evaluate a single im dose of motavizumab treatment of children with RSV (respiratory syncytial virus) illness. NCT00435227. Available from: www.clinicaltrials.gov [Last updated 31 October 2011]
6. Astra-Zeneca. Pipeline Table: motavizumab. Financial Information: 2011 Financial Results. Second quarter and half year results 2011. Available from: http://www.astrazeneca.com/Investors/financial-information/Financialresults [Accessed on 7 November 2011]
7. Synagis® package insert. MedImmune, LLC. Product information as of April 2011.